347 related articles for article (PubMed ID: 21388266)
1. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
[TBL] [Abstract][Full Text] [Related]
2. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
Brodniewicz-Proba T
Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
[TBL] [Abstract][Full Text] [Related]
3. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
4. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States.
Hennessy S; Leonard CE; Platt R
Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450
[TBL] [Abstract][Full Text] [Related]
5. Assessing the bioequivalence of biosimilars The Retacrit case.
Schellekens H
Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
[TBL] [Abstract][Full Text] [Related]
6. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
Cai XY; Thomas J; Cullen C; Gouty D
Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
8. Bioanalytical challenges of biosimilars.
Islam R
Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
[TBL] [Abstract][Full Text] [Related]
9. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
10. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
11. The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
[TBL] [Abstract][Full Text] [Related]
12. Concept of biosimilar products in Jordan.
Haddadin RD
Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
[TBL] [Abstract][Full Text] [Related]
13. Comparative testing and pharmacovigilance of biosimilars.
Locatelli F; Roger S
Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
15. Registration of similar biological products--Singapore's approach.
Poh J; Tam KT
Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381
[TBL] [Abstract][Full Text] [Related]
16. [Biosimilar: can we manage biopharmaceutical heterogeneity?].
Ranieri E
G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296
[No Abstract] [Full Text] [Related]
17. Regulatory guideline for biosimilar products in Korea.
Suh SK; Park Y
Biologicals; 2011 Sep; 39(5):336-8. PubMed ID: 21784653
[TBL] [Abstract][Full Text] [Related]
18. Statistical assessment of biosimilar products.
Chow SC; Liu JP
J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
[TBL] [Abstract][Full Text] [Related]
19. Quality, safety and efficacy of follow-on biologics in Japan.
Yamaguchi T; Arato T
Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
Malhotra H
Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
